Nektar Therapeutics Finalizes $432M Public Offering at Deep Discount, Upsizing Prior Plan

summarizeSummary

Nektar Therapeutics finalized an upsized public offering, raising $432.0 million in net proceeds through the sale of common stock and pre-funded warrants at a deep discount to the current market price, resulting in significant shareholder dilution.

check_boxKey Events

• Offering Finalized and Upsized

  Nektar Therapeutics finalized its public offering, raising approximately $432.0 million in net proceeds, an increase from the $300 million offering previously disclosed on February 10, 2026.

• Significant Dilution

  The offering includes 6,603,449 shares of common stock, 293,103 pre-funded warrants, and an additional 1,034,482 shares from the underwriters' fully exercised option, totaling 7,931,034 new shares, which represents substantial dilution for current shareholders.

• Deep Discount Pricing

  Shares and pre-funded warrants were priced at $58.00 each, a notable discount compared to the current stock price of $69.90, despite the company trading near its 52-week high.

• Use of Proceeds

  Net proceeds will be allocated to general corporate purposes, including research and development, clinical development (specifically Phase 3 trials for rezpegaldesleukin), and manufacturing costs to support drug candidates.

auto_awesomeAnalysis

Nektar Therapeutics has finalized the terms of its public offering, securing approximately $432.0 million in net proceeds. This offering, which was upsized from a previously announced $300 million plan, involves the sale of common stock and pre-funded warrants at a price of $58.00 per share. The total shares to be issued, including those from the underwriters' fully exercised option, amount to 7,931,034, representing substantial dilution for existing shareholders. The pricing of the offering at a deep discount to the current market price of $69.90, especially while the stock is trading near its 52-week high, indicates a significant need for capital. The company intends to use these proceeds for general corporate purposes, including critical research and development, clinical development (notably Phase 3 trials for rezpegaldesleukin), and manufacturing costs, which are essential for advancing its pipeline following recent positive clinical results.